Showing results (71-80 of 90) with videos related to
Sort By:
Pageof 9
Therapeutic Advances in Medical Oncology|May 13, 2022
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experienceVincenza Caputo, Vincenzo De Falco, Anna Ventriglia, et al.Journal of Experimental & Clinical Cancer Research : CR|March 29, 2022
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trialCarminia Maria Della Corte, Morena Fasano, Vincenza Ciaramella, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 11, 2023
Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAFV600E-Mutant Colorectal CancerStefania Napolitano, Melanie Woods, Hey Min Lee, et al.JAMA Network Open|April 9, 2024
Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer: A Nonrandomized Controlled TrialDavide Ciardiello, Erika Martinelli, Teresa Troiani, et al.Biomedicines|April 27, 2024
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung CancerCaterina De Rosa, Francesca Iommelli, Viviana De Rosa, et al.Journal of Translational Medicine|November 24, 2022
Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLCCarminia Maria Della Corte, Vincenza Ciaramella, Kavya Ramkumar, et al.Medical Oncology (Northwood, London, England)|February 11, 2021
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotypeDavide Ciardiello, Bernadette Blauensteiner, Nunzia Matrone, et al.The Oncologist|July 11, 2022
Alarming Drop in Early Stage Colorectal Cancer Diagnoses After COVID-19 Outbreak: A Real-World Analysis from the Italian COVID-DELAY StudyGiulia Mentrasti, Luca Cantini, Clizia Zichi, et al.International Journal of Cancer|July 1, 2023
Panitumumab plus trifluridine/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trialStefania Napolitano, Davide Ciardiello, Vincenzo De Falco, et al.Molecular Oncology|July 20, 2019
Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancerElena Elez, Chiara Chianese, Enrique Sanz-García, et al.Pageof 9